The European Union (EU) Clinical Trials Regulation Nº 536/2014 came into force on 31 January 2022, repealing the Clinical Trials Directive and improving the harmonisation of clinical trials regulation throughout the EU and European Economic Area (EEA). To implement this regulation, the EU introduced the Clinical Trial Information System (CTIS).
CTIS is the single-entry point for submitting clinical trial information in the EU/EEA and supports the flow of information between clinical trial sponsors and regulators. CTIS contains a secure workspace for sponsors, their delegates and authorities for the management of clinical trials. There is also a public area where detailed information can be accessed on all clinical trials conducted in the EU/EEA. CTIS is one of the most significant aspects of implementation of the EU CTR and has come with its own unique challenges.
Getting started with CTIS and OMS
CTIS interacts with several EU databases and systems. These are all managed by EMA and allow users to search for information on organisations and medicinal products which can be selected in CTIS.
Step 1: EMA user account creation
The first step to access the CTIS sponsor workspace is for users to have an EMA account.
- If users already use other EMA applications, they will already have an EMA account and their existing login details can be used to access CTIS
- If users do not have an active EMA account, an account would need to be created via the EMA Account Management Portal. The process is described on the EMA Account Management homepage. Creation of a new account can take up to 2 business days.
Users should complete their profile by adding their employer organisation, which would need to be registered in the Organisation Management Service (OMS) system.
Step 2: Organisation registration
The second step for organisations is to review the OMS. This system is in EMA’s SPOR portal and provides a single validated source of organisation data for CTIS, including organisation names and location addresses.
All organisations participating in a clinical trial should be registered in OMS to be selected in CTIS. This includes sponsors, co-sponsors, third party contractors (e.g., CROs), EEA trial sites and marketing authorisation holders. Once registered, a user can retrieve details for the organisation to populate in the clinical trial application in CTIS.
EMA has recently introduced the option of organisation registration directly in CTIS if organisations participating in a clinical trial are not yet or can’t be registered in OMS. However, organisations that are created locally in CTIS are not validated by EMA. Therefore, users are encouraged to keep in mind the OMS data quality standard set when they create their organisations in CTIS to reduce receipt of RFIs from assessing authorities regarding inaccurate data.
To understand whether an organisation is registered in OMS, users will first need to search for and view the full details of an Organisation and its locations in OMS.
If the user:
- Cannot find the organisation, they can create a brand new organisation
- Finds the organisation but not its location, they can submit a change request to add a new location to the organisation
- Finds both the organisation and its location, but either of these are not up to date, they can submit a change request to update the organisation and/or location data
- Finds the organisation with an active status but the location with an inactive status, they can submit a change request to update the organisation data or add new locations
To complete these actions, users should follow the instructions as described in the “E – OMS Change Requests” guidance document and include any relevant supporting documents with their change requests.
Submission of a new organisation or change request can take 5-10 business days for EMA validation.
Step 3: CTIS high level sponsor administrator registration
Once an organisation is registered in OMS, sponsor organisations must then register a high-level administrator via the EMA Account Management.
This high-level administrator plays an important role in CTIS user management as they are responsible for the allocation of business roles and permissions to users working for, or on behalf of, their organisation. There are no limitations on the number of high-level administrators.
To request this role, users should:
1. Access the EMA Account Management. Select “Manage Access” and “Request Access for Organisations”
2. Select the applicable organisation
3. A list of roles that can be selected for this organisation will be shown:
a. CTIS High Level Sponsor Administrator Role – user must select this role.
b. External Organisation Administrator – this is an optional “super user” role and can be requested once for an organisation. With this role sponsors can approve the First CTIS High Level Sponsor Administrator Role themselves as well as other roles related to European syste
4. An Affiliation Letter Template proving the organisation’s authorisation is required when submitting the request for this registration. Details to this registration process can be found in Module 07 of the CTIS Training Material Catalogue.
This step can take 2-3 business days for EMA validation.
Step 4: CTIS high level sponsor administrator – creating a trial
Once the sponsor high-level administrator is registered, the user will need to request and approve themselves as the “all trials” CT Administrator role in CTIS, which will allow them to have the permissions to create clinical trials, using the “+ New trial” button.
It is very important that the sponsor entity who creates the trial is the same sponsor entity to be used on the protocol and other study documents. Please note, permissions to create a trial are retained by the sponsor unless a CT Administrator for “All Trials” is provided to the chosen representative.
Once a trial is created, the sponsor high-level administrator can delegate roles to the representative based on study scope e.g., CRO CT Administrator (trial specific).
Interface with XEVMPD: Medicinal product registration
The extended EudraVigilance medicinal product dictionary (XEVMPD) includes all medicinal products that are authorised or in development in a clinical trial in the EU/EEA.
All products authorised and unauthorised investigational medicinal products, as well as auxiliary medicinal products must be included in CTIS as part of the clinical trial submission. It is important that products are registered in XEVMPD at a very early stage in the clinical trial submission preparation process otherwise they cannot be selected in CTIS during the CTIS application form. A placebo can be added manually in CTIS without resorting to registration in XEVMPD.
EMA offers detailed information on XEVMPD registration, usage, FAQs and training materials. These are referenced in the CTIS Sponsor Handbook.
Conclusion
Setting up clinical trials under the EU CTR and the implementation of CTIS represent pivotal changes in the European clinical trials landscape. These advancements are aimed at harmonising regulations, increasing transparency, and streamlining the submission and management of clinical trial data.
Embracing the EU CTR and CTIS is essential for conducting clinical trials within the EU and EEA. The increased transparency, regulatory coordination, and improved management of clinical trial data will ultimately benefit both sponsors and the broader healthcare community.
While the new regulation and CTIS come with their challenges, guidance and support are available to assist sponsors and organisations through the process. ICON’s CTIS experts draw from their wealth of experience to provide flexible CTIS support to sponsors who are new to CTIS and OMS, providing valuable insights and guidance for the best use of the system.
References
- https://health.ec.europa.eu/system/files/2016-11/reg_2014_536_en_0.pdf
- https://register.ema.europa.eu/identityiq/help/selfregister.html
- https://spor.ema.europa.eu/omswi/#/
- https://spor.ema.europa.eu/omswi/#/viewDocuments
- https://register.ema.europa.eu/identityiq/login.jsf
- Affiliation Letter Template
- https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/training-support/clinical-trials-information-system-ctis-online-training-modules
- https://www.ema.europa.eu/en/human-regulatory/post-authorisation/data-medicines-iso-idmp-standards/extended-eudravigilance-medicinal-product-dictionary-xevmpd-training
- https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-sponsor-handbook_en.pdf
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel